Introduction: Early prognostic factors for the clinical response in patients with rheumatoid
INTRODUCTION
Rheumatoid arthritis (RA) is the most common and prototypical inflammatory arthropathy in adults. Tumor necrosis factor (TNF)-a plays an important role in the pathogenesis of RA and is considered a main therapeutic target of this disease [1, 2] . Infliximab (IFX) was the first chimeric anti-TNF-a antibody developed to treat RA and has demonstrated high efficacy in a number of studies, including the ATTRACT, BeSt, ASPIRE, and RECONFIRM studies [3] [4] [5] [6] .
The RISING study [7] and its subanalysis [8] intensively investigated factors associated with disease activity in patients with an inadequate response to methotrexate (MTX) after 1 year of treatment. This study divided patients into four groups using a combination of IFX serum trough level and interleukin (IL)-6 serum level at 1 year and found that the most favorable clinical response at this time was in the group with a high IFX serum trough level and low IL-6 serum level. These findings indicated that IFX's control of disease activity at 1 year depended on the degree of neutralization of not only TNF-a but also IL-6.
In addition, a subsequent subanalysis of the RISING study regarding the association of disease activity after 3 months of treatment with efficacy at 1 year [9] concluded that patients with lower activity at 3 months had a high probability of remission at 1 year. In that study, IFX dose and intervals were programmed and continued for 1 year as described in the study protocol. However, in clinical practice dose and interval are optimized for each patient using the treat-to-target (T2T) approach.
Serum TNF-a concentration at baseline is a prognostic factor for requirement of IFX administration [10, 11] . However, the optimal selection of biologics depends on a number of key factors, and optimum dose and interval for Patients were classified into the following groups at 3 and 6 months: IFX-high/IL-6-high group, IFX-high/IL-6-low group, IFX-low/ IL-6-low group, and IFX-low/IL-6-high group.
Cut-off values were based on the RISING study at 1.0 lg/mL for IFX serum trough level and 10 pg/mL for IL-6 serum level [7, 8] . according to the protocol of the RISING study [7, 8] . To explore prognostic factors at baseline or early phase for clinical disease activity, univariate and multivariate analysis were applied. Variables were selected using a stepwise method. Cut-off values were determined using the receiver operating characteristics (ROC) curve. P values \0.05
were considered significant. All analyses were conducted using JMP10 software, version 11.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS

Patient Background
Baseline characteristics of the 35 patients are shown in Table 1 Table 2 ). Serum matrix metalloproteinase-3 (MMP-3) levels and DAS28-CRP were also significantly reduced after 3 months.
Chronological changes in representative values
are shown in Figure S1 in the supplementary material.
Serum trough level of IFX was 2.92 lg/mL (median) at 3 months, which exceeds the 1 lg/ mL considered as the minimally effective concentration.
This concentration was maintained until 1 year. The percentage of patients with serum IFX concentration of more than 1 lg/mL was over 70% of all patients. Serum levels of GM-CSF, IFN-c, IL-12, and IL-6 were significantly reduced at 1 year compared to those at baseline.
Remarkably, IL-6 was dramatically reduced from 4.29 pg/ml at baseline to 0.36 pg/mL at 1 year (P\0.0001). 
\0.0001
Tender joint count (0-28)
Swollen joint count (0-28) Comparison of disease activity among the four groups showed significant differences at both 3 and 6 months. Namely, disease activity was lower in the IFX-high/IL-6-low and IFX-low/ IL-6-low groups. In addition, serum CRP levels were lower in these groups. However, in contrast to the RISING study serum levels of rheumatoid factor, anti-citrullinated peptide antibody, and MMP-3 did not differ between groups [7, 8] .
To confirm a direct association between the IFX serum trough level and clinical response, patients were divided using the same cut-off values into IFX-high and -low groups and disease activity was compared at 3 and 6 months. Disease activity tended to be lower in the IFX-high group at both 3 and 6 months.
These results suggest that serum IL-6 level, rather than IFX serum trough level, potentially reflects TNF-a inhibition and disease activity.
Further, prediction of disease activity at 1 year was attempted using the classification model, a combination IFX serum trough level and IL-6 serum level at 3 and 6 months. However, no significant association was observed.
Association Between Serum Cytokine Levels at Baseline and Clinical Response at 1 Year
To identify baseline factors associated with efficacy at 1 year, correlations between clinical parameters and serum cytokine levels at baseline to disease activity at 1 year were compared by univariate analysis. Although clinical parameters at baseline were not Table 3 . To determine independent variables for prognosis, we then conducted a multivariate analysis. Notably, IL-6 and IL-10 were associated with disease activity as evaluated by DAS28-ESR at 1 year (Table 4) . When CDAI was used for evaluation, IL-2, -6, and -10 were associated with disease activity. In categorical classifications, IL-6 and IL-10 were associated 
DISCUSSION
In this single-center, observational and investigational cohort study, we demonstrated that IL-6 serum level rather than IFX serum trough level was associated with disease activity at 3 and 6 months after the initiation of IFX treatment. In addition, serum levels of IL-6 and IL-10 at baseline were significantly associated with efficacy after 1 year of treatment with IFX for RA patients with an inadequate response to MTX.
Several studies have analyzed the kinetics of serum inflammatory cytokines following IFX administration [7, 8, [14] [15] [16] [17] . In some of these studies, serum levels of IL-6 decreased in response to IFX administration [14] [15] [16] . Fourteen weeks after the initiation of IFX P values are indicated ACPA anti-citrullinated peptide antibody, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score 28, ESR erythrocyte sedimentation rate, GM-CSF granulocyte-macrophage colony-stimulating factor, HAQ-DI Health Assessment Questionnaire-Disability Disability Index, IFN interferon, IL interleukin, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, SDAI Simplified Disease Activity Index, TNF tumor necrosis factor, VAS visual analogue scale administration, a decrease in the serum concentration was observed for IL-6, but not for TNF-a [14, 15] . Regarding reports of earlier time points following the initiation of IFX administration, the serum level of IL-6 was immediately reduced and maintained, whereas that of TNF-a was temporarily increased and recovered to baseline level [16] . In the current study, a significant decrease in the serum level of IL-6 at 3 months compared to baseline and a trend for a further reduction at 6 months and 1 year was observed. However, the serum concentration of TNF-a did not change during the 1-year period, which is consistent with the reports above. In addition, when using the optimized administration method based on the T2T approach, the dose and intervals of IFX administration were not constant and serum levels of IL-6 significantly decreased over the 1-year period. This sequential observational study over 1 year to be is therefore considered to be unique and to give considerable weight to routine clinical practice.
Few reports have described serum factors prognostic for the efficacy of IFX. One reported prognostic factor is baseline serum concentration of TNF-a [7, 8] . Another report indicated that IL-1b concentration in whole blood stimulated by lipopolysaccharide was prognostic of efficacy at 6 months after the initiation of IFX treatment [17] . The current study clearly demonstrates that baseline serum concentrations of both IL-6 and IL-10 are prognostic for the efficacy of IFX treatment at 1 year.
IL-6 is a proinflammatory cytokine which is strongly associated with the pathophysiology of RA. In contrast, IL-10 is considered a pleiotropic cytokine with suppressive functions, and its role in RA is controversial. The serum concentration of IL-10 was reportedly not affected by 1 month of treatment with IFX [7] . Increases in the serum concentration of IL-10 were observed in patients with RA compared to healthy controls [18] . In addition, IL-10-deficient animal models manifest arthritis-exacerbated bone erosion [19] . Further, TNF-a inhibition was reported to induce IL-10 production from CD4
? T cells [20] . 
CONCLUSIONS
In 
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